+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Statin therapy and secretory phospholipase A₂ in children with heterozygous familial hypercholesterolemia



Statin therapy and secretory phospholipase A₂ in children with heterozygous familial hypercholesterolemia



Atherosclerosis 229(2): 404-407



Secretory phospholipase A2 (sPLA2) enzymes are thought to contribute to atherosclerosis. In this study we assessed levels of sPLA2 mass and activity, and their relationship to baseline characteristics of children with familial hypercholesterolemia (FH). Furthermore, we evaluated the effect of two years of pravastatin therapy on sPLA2 levels. sPLA2-IIA mass and sPLA2 activity were measured at baseline and after two years in 187 children with FH (aged 8-18 years) randomized to pravastatin or placebo. At baseline, median [IQR] sPLA2-IIA mass and sPLA2 activity levels were 7.2 [5.8 to 13.2] ng/ml and 36.4 [29.8-47.1] U/ml, respectively. Both sPLA2-IIA mass and sPLA2 activity were significantly correlated with high-sensitivity C-reactive protein (r=0.33, p<0.001 and r=0.386, p<0 .001, respectively), but not with other cardiovascular risk factors. Baseline levels of sPLA2-IIA mass and sPLA2 activity were not significantly associated with carotid intima-media thickness (cIMT) at baseline or at the end of follow-up. After two years, sPLA2-IIA mass and sPLA2 activity levels were not significantly reduced in the pravastatin group (p=0.20 and p=0.63, respectively), nor in the placebo group (p=0.17 and p=0.11, respectively). Changes from baseline did not differ between the treatment groups for sPLA2-IIA mass (p=0.48) and sPLA2 activity (p=0.88). sPLA2-IIA mass and sPLA2 activity were not significantly associated with cIMT in our paediatric FH cohort. This could indicate that the potential predictive role of sPLA2 as a biomarker of cardiovascular disease in children with FH is limited. Treatment with pravastatin did not reduce sPLA2-IIA mass or sPLA2 activity levels, as compared to placebo. Further studies with larger samples are required to address these issues.

(PDF emailed within 0-6 h: $19.90)

Accession: 055911205

Download citation: RISBibTeXText

PMID: 23880195

DOI: 10.1016/j.atherosclerosis.2013.05.023


Related references

Statin therapy and risk of diabetes in patients with heterozygous familial hypercholesterolemia or familial combined hyperlipidemia. Atherosclerosis 237(1): 140-145, 2015

Statin Therapy and Risk of Diabetes Mellitus in Aging Patients With Heterozygous Familial Hypercholesterolemia or Familial Combined Hyperlipidemia: A 10-Year Follow-Up. Angiology 69(3): 242-248, 2017

Elevated remnant-like particles in heterozygous familial hypercholesterolemia and response to statin therapy. Circulation 106(7): 788-792, 2002

Evolution of thoracic aorta atherosclerosis in patients with heterozygous familial hypercholesterolemia after statin therapy. Journal of the American College of Cardiology 31(2 SUPPL A): 281A, 1998

Plasma lipoprotein(a) levels and LDL-cholesterol lowering response to statin therapy in patients with heterozygous familial hypercholesterolemia. Annals of Clinical and Laboratory Science 36(3): 353-355, 2006

Proportion of oxidized LDL relative to plasma apolipoprotein B does not change during statin therapy in patients with heterozygous familial hypercholesterolemia. Atherosclerosis 185(2): 307-312, 2005

Elevated PCSK9 levels in untreated patients with heterozygous or homozygous familial hypercholesterolemia and the response to high-dose statin therapy. Journal of the American Heart Association 2(2): E000028-E000028, 2013

Lipoprotein-associated phospholipase A2 mass and activity in children with heterozygous familial hypercholesterolemia and unaffected siblings: effect of pravastatin. Journal of Clinical Lipidology 5(1): 50-56, 2011

Diabetogenic effects of high intensity statin treatment in heterozygous familial hypercholesterolemia and familial combined hyperlipidemia. Atherosclerosis 235(2): E56-E57, 2014

Impact of statin treatment on the clinical fate of heterozygous familial hypercholesterolemia. Journal of Atherosclerosis and Thrombosis 17(7): 667-674, 2010

Ten-year follow-up after initiation of statin therapy in children with familial hypercholesterolemia. JAMA 312(10): 1055-1057, 2014

Early statin therapy restores endothelial function in children with familial hypercholesterolemia. Journal of the American College of Cardiology 40(12): 2117-2121, December 18, 2002

A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology 27(8): 1803-1810, 2007

Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA 292(3): 331-337, 2004

Efficacy and Safety of Statin Therapy in Children With Familial Hypercholesterolemia: A Randomized Controlled Trial. Yearbook of Pediatrics 2006: 230-232, 2006